Erenumab
(Anti-human CGRP mAb, human IgG2-Lambda; AMG-334)
Catalog No.: PC-Ab1070Not For Human Use, Lab Use Only.
Erenumab (AMG-334) is a fully human monoclonal antibody that selectively and potently binds to the canonical CGRP (calcitonin gene-related peptide receptor). Erenumab (AMG-334) competes with [(125)I]-CGRP binding to the human CGRP receptor, with a Ki of 0.02 nM. AMG 334 fully inhibited CGRP-stimulated cAMP production with an IC50 of 2.3 nM in cell-based functional assays (human CGRP receptor) and was 5000-fold more selective for the CGRP receptor than other human calcitonin family receptors, inc
Erenumab (AMG-334) is a fully human monoclonal antibody that selectively and potently binds to the canonical CGRP (calcitonin gene-related peptide receptor). Erenumab (AMG-334) competes with [(125)I]-CGRP binding to the human CGRP receptor, with a Ki of 0.02 nM. AMG 334 fully inhibited CGRP-stimulated cAMP production with an IC50 of 2.3 nM in cell-based functional assays (human CGRP receptor) and was 5000-fold more selective for the CGRP receptor than other human calcitonin family receptors, including adrenomedullin, calcitonin, and amylin receptors. Erenumab blocks the activation of calcitonin gene-related peptide (CGRP), which can cause blood vessels to dilate and ellicit inflammation and migraine headache pain. Erenumab is used to prevent migraine headaches in adults.
Physicochemical Properties
M.Wt
Formula
Human IgG2-Lambda
Appearance
Solid
CAS No.
Storage
Solide Powder
-20 °C 12 Months; 4°C 6 Months
In Solvent
-80 °C 6 Months; -20°C 6 Months
Shipping
Solubility
PBS, pH 7.0
Contains no stabilizers or preservatives
